NEW YORK (GenomeWeb) – Roche said today that its diagnostics division revenues grew 5 percent in the first nine months of 2017, driven by growth in immunodiagnostics and in the rest of its centralized and point-of-care solutions business.

For the nine months ended Sept. 30, the Basel, Switzerland-based pharmaceuticals and diagnostics firm's total revenues rose 5 percent to CHF 39.43 billion ($40.61 billion) from CHF 37.51 billion during the same period in 2016.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.